Clinica Medica II, Centro Ipertensione e Fisiopatologia Cardiovascolare, Department of Internal Medicine and Therapeutics, University of Pavia, Italy.
Adv Ther. 2010 Jan;27(1):48-55. doi: 10.1007/s12325-010-0002-0. Epub 2010 Feb 19.
The objective of this study was to compare the effect on ankle edema of adding valsartan (V) or olmesartan (O) to amlodipine (A) in the treatment of hypertension.
After a 4-week placebo period, 74 adult outpatients with essential hypertension (diastolic blood pressure [DBP] >90 and <110 mmHg, and systolic blood pressure [SBP] >140 mmHg) were treated with A 10 mg once daily for 4 weeks. Thereafter, nonresponder patients (DBP >90 mmHg and/or SBP >140 mmHg; n=51) were randomized to receive additional V 160 mg once daily or O 20 mg once daily for 8 weeks in two crossover periods, each separated by a 4-week placebo period. Clinic blood pressure (BP), heart rate, and ankle/foot volume (AFV) were evaluated and blood samples were drawn to evaluate plasma norepinephrine (NE) levels.
Both V/A and O/A induced a greater SBP/DBP reduction than A monotherapy (-26.4/-20.8 mmHg and -24.4/-19.1 mmHg, respectively; all P<0.001 vs. baseline and P<0.01 vs. A). A monotherapy increased AFV by 24%, P<0.001 vs. baseline, while the addition of either V or A reduced such increases. However, with V/A the AFV increase (+9.7%, P<0.05 vs. baseline, P<0.01 vs. A) was lower than with O/A (+16.7%, P<0.01 vs. baseline, P<0.05 vs. A); the difference between the two combinations was significant. Plasma NE levels were significantly increased by A (+44.6%) and values did not change with the addition of V (+35.2%) or O (+33.7%). Plasma active renin (PAR) was unchanged by A but increased by V/A (+214.4%, P<0.05 vs. baseline) and further by O/A (+325.6%, P<0.01 vs. baseline; difference between the 2 combinations: P<0.05). An inverse correlation was found between the AFV decrease and PAR increase (r=-0.31, P<0.05).
Adding V or O to A reduced ankle edema, but this effect was more pronounced with V. The greater degree of renin-angiotensin system activation observed with Ocould be related to such a difference.
本研究的目的是比较在氨氯地平(A)治疗高血压的基础上加用缬沙坦(V)或奥美沙坦(O)对踝部水肿的影响。
74 例成年原发性高血压患者(舒张压[DBP]>90mmHg 且<110mmHg,收缩压[SBP]>140mmHg)在 4 周安慰剂期后,给予 A 10mg 每日 1 次治疗 4 周。此后,无应答患者(DBP>90mmHg 和/或 SBP>140mmHg;n=51)随机分为两组,在 4 周安慰剂期之间进行 8 周的双交叉治疗,分别加用 V 160mg 每日 1 次或 O 20mg 每日 1 次。评估诊室血压(BP)、心率和踝/足部容积(AFV),抽取血样以评估血浆去甲肾上腺素(NE)水平。
与 A 单药治疗相比,V/A 和 O/A 均可显著降低 SBP/DBP(分别降低-26.4/-20.8mmHg 和-24.4/-19.1mmHg;均 P<0.001 与基线相比,P<0.01 与 A 相比)。A 单药治疗可使 AFV 增加 24%,P<0.001 与基线相比,而加用 V 或 O 可减少这种增加。然而,与 O/A 相比,V/A 时的 AFV 增加(+9.7%,P<0.05 与基线相比,P<0.01 与 A 相比)较低,而 O/A 时的 AFV 增加(+16.7%,P<0.01 与基线相比,P<0.05 与 A 相比);两种联合治疗之间的差异具有统计学意义。A 可显著增加血浆 NE 水平(增加 44.6%),而加用 V(增加 35.2%)或 O(增加 33.7%)后,NE 水平无变化。A 不改变血浆活性肾素(PAR),但 V/A 可使 PAR 增加(增加 214.4%,P<0.05 与基线相比),而 O/A 可使 PAR 进一步增加(增加 325.6%,P<0.01 与基线相比;两种联合治疗之间的差异:P<0.05)。AFV 下降与 PAR 增加呈负相关(r=-0.31,P<0.05)。
在 A 基础上加用 V 或 O 可减轻踝部水肿,但 V 的效果更显著。与 O 观察到的肾素-血管紧张素系统激活程度更大可能与这种差异有关。